Ixico PLC | Income Statement

Fiscal year is October-September. All values GBP Thousands.
2012
2014
2015
2016
2017
2018
Sales/Revenue
18.70
2,559.80
3,115.00
3,268.00
4,110.00
5,394
Cost of Goods Sold (COGS) incl. D&A
26.90
1,110.80
1,472.00
2,027.00
1,978.00
2,373
Gross Income
8.20
1,449.00
1,643.00
1,241.00
2,132.00
3,021
SG&A Expense
9,365.10
3,148.50
3,912.00
4,299.00
4,094.00
4,369
EBIT
9,373.30
1,901.30
2,269.00
-
1,962.00
1,348
Unusual Expense
-
938.00
367.00
706.00
481.00
-
Non Operating Income/Expense
77.40
865.30
1,111.00
759.00
404.00
425
Pretax Income
9,084.40
1,960.50
1,524.00
3,004.00
2,039.00
919
Income Tax
1,318.10
241.50
330.00
885.00
512.00
251
Consolidated Net Income
7,766.30
1,719.00
1,194.00
2,119.00
1,527.00
668
Net Income
7,766.30
1,719.00
1,194.00
2,119.00
1,527.00
668
Net Income After Extraordinaries
7,766.30
1,719.00
1,194.00
2,119.00
1,527.00
668
Net Income Available to Common
7,766.30
1,719.00
1,194.00
2,119.00
1,527.00
668
EPS (Basic)
1.10
0.11
0.08
0.09
0.06
0.02
Basic Shares Outstanding
-
15,059.00
15,057.20
24,349.10
26,929.60
33,761.40
EPS (Diluted)
-
0.11
0.08
0.09
0.06
0.02
Diluted Shares Outstanding
-
15,416.00
15,416.00
24,349.10
26,929.60
33,761.40
EBITDA
9,346.40
1,765.50
2,120.00
2,711.00
1,770.00
1,196
Other Operating Expense
-
201.80
-
-
-
-
Non-Operating Interest Income
211.50
13.50
1.00
1.00
-
4

About Ixico

View Profile
Address
Griffin Court
London Greater London EC1A 9PN
United Kingdom
Employees -
Website http://ixico.com/
Updated 07/08/2019
IXICO Plc engages in the provision of technology-enabled specialty services to the global biopharmaceutical industry. Its services are used to select patients for clinical trials, assess the safety and efficacy of new drugs in development, and in post marketing surveillance. The company was founded by Derek Lionel Glendon Hill on November 28, 1995 and is headquartered in London, the United Kingdom.